^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AUR-109

    i
    Other names: AUR-109, ODM-203, ODM203, ODM 203
    Associations

    News

    Trials
    Company:
    Dr. Reddy’s, Orion Corp
    Drug class:
    RTK inhibitor
    Related drugs:
    Associations

    News

    Trials
    5d
    TEJAS-2: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers (clinicaltrials.gov)
    P2, N=29, Terminated, Aurigene Discovery Technologies Limited | N=90 --> 29 | Trial completion date: May 2027 --> Feb 2026 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Feb 2026; Patient recruitment problems.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • MSI (Microsatellite instability) • FOLR1 ( Folate receptor alpha ) • BRCA (Breast cancer early onset)
    |
    MSI-H/dMMR • HER-2 amplification • KRAS wild-type • RAS wild-type • BRCA mutation
    |
    AUR-109
    over1year
    TEJAS-2: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers (clinicaltrials.gov)
    P2, N=90, Recruiting, Aurigene Discovery Technologies Limited
    New P2 trial
    |
    AUR-109
    over5years
    Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. (PubMed, ESMO Open)
    This study suggests ODM-203 400 mg/day results in sufficient plasma concentrations and acceptable tolerability in most patients. Preliminary signs of therapeutic activity of ODM-203 in patients with solid tumours was observed.
    Clinical • P1/2 data • Journal
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    AUR-109